Asia Pacific Small Molecule Innovator Api Cdmo Market Size & Outlook
Related Markets
Asia Pacific small molecule innovator api cdmo highlights
- The Asia Pacific small molecule innovator api cdmo generated a revenue of USD 13,462.1 million in 2024.
- The market is expected to grow at a CAGR of 6.9% from 2025 to 2030.
- In terms of segment, clinical was the largest revenue generating stage type in 2024.
- Commercial is the most lucrative stage type segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2025 to 2030.
Asia Pacific data book summary
| Market revenue in 2024 | USD 13,462.1 million |
| Market revenue in 2030 | USD 20,301.9 million |
| Growth rate | 6.9% (CAGR from 2025 to 2030) |
| Largest segment | Clinical |
| Fastest growing segment | Commercial |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Preclinical, Commercial, Clinical |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, Thermo Fisher Scientific Inc, Siegfried Holding AG, Recipharm, CordenPharma, Samsung BioLogics, Labcorp Holdings Inc, Ajinomoto Co Inc, Piramal Pharma Solutions, Jubilant Biosys, Wuxi AppTec Co Ltd |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 41.7% of the global small molecule innovator api cdmo in 2024.
- Globally, Asia Pacific is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 20,301.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Small Molecule Innovator API CDMO Scope
Small Molecule Innovator API CDMO Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| CordenPharma | View profile | 5001-10000 | Plankstadt, Baden-Wurttemberg, Germany, Europe | http://cordenpharma.com |
| Jubilant Biosys | View profile | 501-1000 | Bengaluru, Karnataka, India, Asia | https://www.jubilantbiosys.com/ |
| Piramal Pharma Solutions | View profile | 1001-5000 | Riverview, Michigan, United States, North America | http://www.piramalpharmasolutions.com/ |
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | https://www.samsungbiologics.com/ |
| Recipharm | View profile | 1001-5000 | Jordbro, Stockholms Lan, Sweden, Europe | http://www.recipharm.com |
| Ajinomoto Co Inc | View profile | 43318 | 15-1, Kyobashi 1-chome, Chuo-ku, Tokyo, Japan, 104-8315 | http://www.ajinomoto.co.jp |
| Siegfried Holding AG | View profile | 4180 | Untere Bruehlstrasse 4, Zofingen, Switzerland, CH-4800 | https://www.siegfried.ch |
| Catalent Inc | View profile | 17219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | https://www.catalent.com |
| Wuxi AppTec Co Ltd | View profile | 41116 | 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China, People's Republic of, 200131 | https://www.wuxiapptec.com |
| Labcorp Holdings Inc | View profile | 67000 | 358 South Main Street, Burlington, NC, United States, 27215 | https://www.labcorp.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
Asia Pacific small molecule innovator api cdmo outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to small molecule innovator api cdmo will help companies and investors design strategic landscapes.
Clinical was the largest segment with a revenue share of 58.1% in 2024. Horizon Databook has segmented the Asia Pacific small molecule innovator api cdmo based on preclinical, commercial, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
- Asia Pacific Small Molecule Innovator API CDMO Stage Type Outlook (Revenue, USD Million, 2018-2030)
- Preclinical
- Commercial
- Clinical
- Phase I
- Phase II
- Phase III
- Asia Pacific Small Molecule Innovator API CDMO Customer Type Outlook (Revenue, USD Million, 2018-2030)
- Pharmaceutical
- Small
- Medium
- Large
- Biotechnology
- Small
- Medium
- Large
- Pharmaceutical
- Asia Pacific Small Molecule Innovator API CDMO Therapeutic Area Outlook (Revenue, USD Million, 2018-2030)
- Cardiovascular diseases
- Oncology
- Respiratory disorders
- Neurology
- Metabolic Disorders
- Infectious Diseases
- Others
Reasons to subscribe to Asia Pacific small molecule innovator api cdmo databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific small molecule innovator api cdmo databook
-
Our clientele includes a mix of small molecule innovator api cdmo companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific small molecule innovator api cdmo, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific small molecule innovator api cdmo from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific small molecule innovator api cdmo market report size, by country, 2018-2030 (US$M)
Asia Pacific Small Molecule Innovator API CDMO Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
